Fresh analysis reveals that people who come off popular GLP-1 drugs like Mounjaro or Wegovy may regain reduced body mass much more quickly than those who stop conventional diet and exercise regimens.
Findings released in a major health publication shows that while overweight individuals frequently drop about a fifth of their total mass while undergoing treatment, the weight comes back at an average rate of 0.8 kg per month once they quit.
"People buying these treatments must be cognizant of the danger of fast rebound weight gain when the therapy ends," stated lead investigator Dr. Susan Jebb.
That rate of recovery suggests a return to starting weight within about 18 months.
Comparing Approaches
The research, which examined dozens of trials involving thousands of participants, contrasted the outcomes of GLP-1 agonists with older methods.
The team note that individuals who lose weight through lifestyle changes alone typically see a more gradual weight regain—around 100 grams monthly—after stopping.
The Reason for the Fast Rebound
Experts suggest the way of the drugs explains the accelerated rebound.
These medications imitate a natural hormone called glucagon-like peptide-1, which helps regulate appetite.
"Long-term administration of GLP-1 levels far above than normal might result in the system to generate a reduced amount of its own natural hormone, and may also diminish sensitivity to its effects," said Dr. Adam Collins, a dietetics specialist.
"Discontinuation of this hormone supplement leads to appetite is no longer kept in check, making excessive eating far more likely."
An Ongoing Issue?
The NHS recommend the jabs for people with weight-linked health risks, accompanied by recommended diet and exercise modifications.
A number of clinicians contend that, considering the likelihood of weight regain, the therapy might need to be life-long.
This view is supported by pharmaceutical companies, who say that the findings "emphasize the persistent character of excess weight," comparing it to managing diseases like high blood pressure.
Patient Experiences
Users who have stopped the medication report a powerful return of hunger.
"It felt as if something that goes on and you become extremely hungry," described a patient.
This difficulty is compounded if individuals have not adopted permanent dietary or behavioural changes during treatment.
Widespread Interest
Survey data suggest that a significant number of adults in the UK have tried weight-loss jabs in the past year, with demand being substantial.
- Adoption is greater among females than men.
- The middle-aged demographic shows the highest level of interest.
- A large proportion access the drugs through private prescriptions rather than public health services.
Ultimately, experts emphasize that while the jabs are powerful agents for weight loss, they are not a magic cure and long-term success relies on integrated lifestyle changes.
